Consainsights logo

Seasonal Influenza Vaccine Market Size, Share, Industry Trends and Forecast to 2030

Seasonal Influenza Vaccine Market Research Report – Segmented By Region (North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America) – Analysis on Size, Share, Trends, COVID-19 Impact, Competitive Analysis, Growth Opportunities and Key Insights from 2019 to 2030.

  • Published date -30th Jan 2024

  • Formats -PDF, CSV

  • Region -Global

Seasonal Influenza Vaccine Market Size & CAGR in 2021

The seasonal influenza vaccine market had a remarkable market size in 2021, with a CAGR growth rate of 4.5%. The market size was estimated to be USD 6.7 billion in 2021, showing a steady increase in demand for influenza vaccines globally. The rise in awareness regarding the importance of vaccination and the increasing prevalence of influenza cases are some of the key factors driving the growth of the seasonal influenza vaccine market.

COVID-19 Impact on the Seasonal Influenza Vaccine Market

The COVID-19 pandemic had a significant impact on the seasonal influenza vaccine market in 2021. With the outbreak of the pandemic, there was a surge in demand for influenza vaccines as people became more cautious about their health and well-being. This led to a spike in the production and distribution of seasonal influenza vaccines. The pandemic also highlighted the importance of vaccination and preventive measures, thereby boosting the market for seasonal influenza vaccines.

Seasonal Influenza Vaccine Dynamics

The dynamics of the seasonal influenza vaccine market are influenced by various factors such as government initiatives, technological advancements, and the emergence of new strains of influenza viruses. The market is characterized by intense competition among key players who are constantly striving to develop innovative vaccines to cater to the evolving needs of the consumers. Additionally, the increasing focus on research and development activities to enhance the efficacy and safety of seasonal influenza vaccines is driving the growth of the market.

Segments and Related Analysis

The seasonal influenza vaccine market is segmented based on type, technology, age group, and region. The types of vaccines include inactivated vaccines, live attenuated vaccines, recombinant vaccines, and others. The technology segment comprises egg-based, cell-based, and recombinant technology. Age groups range from pediatric to adults and senior citizens. The regional analysis covers North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

By Region Analysis

North America is the largest market for seasonal influenza vaccines, with a significant share in terms of revenue and consumption. The region's advanced healthcare infrastructure, high awareness levels, and government support for vaccination programs contribute to its dominance in the market. Europe follows closely, with a substantial market share driven by the growing aging population and the emphasis on preventive healthcare. The Asia Pacific region is witnessing rapid growth due to increasing investments in healthcare infrastructure and rising awareness about vaccination.

Key Market Players and Competitive Landscape

The seasonal influenza vaccine market is highly competitive, with key players focusing on innovation, strategic collaborations, and product development to maintain their market positions. Some of the leading companies in the market include Sanofi Pasteur, Seqirus, GlaxoSmithKline, AstraZeneca, and CSL Limited. These players are investing heavily in research and development to introduce new and improved vaccines to meet the growing demand for seasonal influenza vaccines.

Recent happenings in the Seasonal Influenza Vaccine Market

In recent years, there have been several developments in the seasonal influenza vaccine market. For instance, Sanofi Pasteur announced the launch of a quadrivalent influenza vaccine for children, providing broader protection against influenza viruses. Seqirus introduced a high-dose influenza vaccine for senior citizens, enhancing the immune response in this vulnerable population. GlaxoSmithKline collaborated with research institutions to develop a universal influenza vaccine that offers long-lasting protection against multiple strains of the virus.

Seasonal Influenza Vaccine Market FAQs